Novartis Gene Therapies Revenue and Competitors
Estimated Revenue & Valuation
- Novartis Gene Therapies's estimated annual revenue is currently $52.4B per year.
- Novartis Gene Therapies's estimated revenue per employee is $64,919,455
- Novartis Gene Therapies's current valuation is $202.6B. (January 2022)
Employee Data
- Novartis Gene Therapies has 807 Employees.
- Novartis Gene Therapies grew their employee count by -16% last year.
Novartis Gene Therapies's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Global VP, Patient Advocacy and Public Affairs | Reveal Email/Phone |
2 | VP Technical Operations and Site Head at Gyroscope Therapeutics, A Novartis Company | Reveal Email/Phone |
3 | Head Quality Systems and Compliance | Reveal Email/Phone |
4 | VP, Global Head Value & Access (formerly AveXis) | Reveal Email/Phone |
5 | Head, Central Eastern Europe | Reveal Email/Phone |
6 | Head Quality Operations | Reveal Email/Phone |
7 | Head Preclinical Manufacturing, Technical R&D | Reveal Email/Phone |
8 | Head Business Operations Region Americas | Reveal Email/Phone |
9 | Head Site Operations Management | Reveal Email/Phone |
10 | Head, PMO Process Development | Reveal Email/Phone |
What Is Novartis Gene Therapies?
At Novartis, we use science-based innovation to address some of society’s most challenging healthcare issues. We discover and develop breakthrough treatments and find new ways to deliver them to as many people as possible.
keywords:N/A
N/A
Total Funding
807
Number of Employees
$52.4B
Revenue (est)
-16%
Employee Growth %
$202.6B
Valuation
N/A
Accelerator
Novartis Gene Therapies News
Backed by $110 million in venture funding, Satellite is led by Dave Lennon, formerly head of Novartis Gene Therapies.
The Food and Drug Administration has cleared a Novartis manufacturing plant in North Carolina to produce commercial-grade gene therapies,...
Novartis Gene Therapies is reimagining medicine to transform the lives of people living with rare genetic diseases. Utilizing cutting-edge...
Novartis bet large on The Medicines Company’s RNAi heart drug inclisiran, expecting to shake up that segment of the market with a swift US approval. But after getting stiff-armed by the FDA last year, the pharma giant’s now releasing more post-hoc data in the hopes of finally running it past the ...
In what might become a new scandal for Novartis, federal investigators recently demanded information from the drug maker (NVS) about the pricing and marketing of one of its biggest-selling drugs, and the focus of the probe includes compensation paid to physicians. Last month, the U.S. Departmen ...
Other Companies in Bannockburn
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | N/A | 2281 | 27% | N/A |
#2 | $3320M | 5760 | 8% | N/A |